CD BioSciences is a growing life science company focusing on 3D bioprinting fields such as bio-ink design, 3D printing technology platform development and in vitro research micro-models customization. Here, our experienced experts can provide you with a series of 3d printing bioinks and solutions based on 3Dmicroflu™ technology platform for you to choose from according to your project needs. In the process of drug development, no matter what type of drug, models are needed for the initial drug screening. CD BioSciences can help you achieve high throughput in drug screening by replacing inaccurate 2D cell and animal models. Do you consider choosing 3Dmicroflu™ technology platform to advance your in vitro drug screening process? The following shows the application of 3Dmicroflu™ technology platform in advancing the small molecule drug development process.
Small molecule drugs are usually organic synthetic compounds with molecular weight less than 1000 g/mol. The structure of small molecule drugs has a good spatial dispersion, which fundamentally determines their good drug-forming properties and pharmacokinetic properties. These characteristics make small molecule drugs exhibit great advantages in drug development process and other drug fields. Small molecule drugs are targeted drugs in terms of mechanism of action. Therefore, small molecule drugs can precisely target specific lesions while accumulating and releasing active ingredients at the target site to achieve therapeutic effects.
Fig. 1. Schematic representation of the action of the small molecule targeted drug at the target cell.
In the development of small molecule targeted drugs, the selection of screening models is very important which can determine the whole process of development. Currently, 3D bioprinting is an emerging field that can contribute to the replacement of traditional animal screening models. At CD BioSciences, we are always committed to promoting our proprietary high-resolution 3D printing technology platform called 3Dmicroflu™, which enables precise and detailed printing. By choosing 3Dmicroflu™ technology platform, the efficiency of your small molecule targeted drug screening will be substantially improved.
Based on the good drug-forming properties and pharmacokinetic properties of small molecule drugs, it is widely used in the treatment of various diseases, such as tumors, autoimmune diseases, neurological diseases, etc. CD BioSciences can provide you with high-resolution in vitro disease micro-model construction for the screening of small molecule targeted drugs. The diagram below shows the general process of 3Dmicroflu™ technology platform involved in small molecule drug development. Based on a series of disease micro-models built by 3Dmicroflu™ technology platform, you can not only discover new targets through disease mechanism studies, but also perform high-throughput screening of small molecule drugs based on identified targets.
Fig. 2. 3Dmicroflu™ technology platform is involved in the construction of disease micro-models for the rapid screening process of small molecule drugs.
In small molecule drug screening, 3Dmicroflu™ technology platform based on 3D bioprinting has the following advantages.
3Dmicroflu™ technology platform has obvious advantages in the screening process of small molecule targeted drugs and can help you to customize a range of drug disease models. The experts from CD BioSciences are professionals and have extensive experience in the field of 3D bioprinting. We believe that with their assistance, your small molecule drug screening process will be much smoother.
If you have a need for the 3Dmicroflu™ technology platform for high-throughput screening of small molecule drugs in your drug development program, please feel free to contact us for customization of the immune organ and system. We always hope that 3Dmicroflu™ technology platform will provide great assistance and guidance to your drug development process.